CMPX — Compass Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$2.31
-$0.08 (-3.35%)
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on NASDAQ. It is led by Thomas J. Schuetz M.D., Ph.D., based in 80 Guest Street, Boston, MA, United States, 02135, with about 39 employees. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Net income was -$14.3M. CMPX currently screens at market cap $367.4M.
Use this CMPX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CMPX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CMPX SEC filings page. Lician reads the product cache first so this HTML stays unique to Compass Therapeutics Inc. even when a live quote feed is slow.
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Key Statistics
Market Cap
$367.38M
Volume
2.28M
Previous Close
$2.40
Day Range
$2.39 – $2.55
EPS
$0.00
Revenue
$0.00
Net Income
-$49.38M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
39
CMPX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$49.38M | -$42.49M | -$39.23M | -$82.18M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$140.40M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$43.48M
Operating Cash Flow
-$44.85M
Free Cash Flow
$0.00
Compass Therapeutics Inc. Company Information
- CEO & Vice Chairman
- Thomas J. Schuetz M.D., Ph.D.
- Headquarters
- 80 Guest Street, Boston, MA, United States, 02135
- Website
- www.compasstherapeutics.com
- Phone
- 617 500 8099
- IPO / Founded
- 2021-04-05
- Sector
- Healthcare
- Industry
- Biotechnology